BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Moura CS, Etingin A, Lukusa L, Singh H, Narula N, Targownik LE, Leung Y, Zezos P, Polewiczowska-Nowak B, Afif W, Bernatsky S. Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics vs biosimilars. World J Gastroenterol 2026; 32(9): 114580 [PMID: 41810446 DOI: 10.3748/wjg.v32.i9.114580]
URL: https://www.wjgnet.com/1007-9327/full/v32/i9/114580.htm
Number Citing Articles
1
Chuong Dinh Nguyen, Luan Minh Dang. Biosimilars in inflammatory bowel disease: Beyond evidence, toward trust and implementationWorld Journal of Gastroenterology 2026; 32(28): 119462 doi: 10.3748/wjg.119462
2
Anthony Vignone, Simone Di Cola, Flaminia Ferri, Francesco Covotta, Lewis J. Frey, Wing-Kin Syn, Domenico Alvaro, Vincenzo Cardinale. Unmet Needs in Primary Sclerosing Cholangitis Associated with Inflammatory Bowel Disease: A Comprehensive ReviewLivers 2026; 6(4) doi: 10.3390/livers6040075